This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Lake Street Sticks to Its Buy Rating for OptimizeRx (OPRX)
Lake Street analyst Eric Martinuzzi maintained a Buy rating on OptimizeRx today and set a price target of $20.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Martinuzzi covers the Technology sector, focusing on stocks such as Cognyte Software, Par Technology, and One Stop Systems. According to TipRanks, Martinuzzi has an average return of 13.1% and a 52.36% success rate on recommended stocks.
OptimizeRx has an analyst consensus of Strong Buy, with a price target consensus of $15.20.
Based on OptimizeRx’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $32.24 million and a net profit of $5.02 million. In comparison, last year the company earned a revenue of $32.32 million and had a GAAP net loss of $78 thousand
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
